Multiple Myeloma Clinical Trials
A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 242 clinical trials
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will …
- 0 views
- 20 Jan, 2023
- 27 locations
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
- 1 views
- 21 Oct, 2022
- 12 locations
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
- 0 views
- 23 Oct, 2022
- 14 locations
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1)
relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
- 0 views
- 25 Oct, 2022
- 2 locations
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …
- 1 views
- 27 Oct, 2022
- 20 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …
- 45 views
- 13 Jan, 2023
- 18 locations
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will …
- 0 views
- 07 Oct, 2022
- 7 locations
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.
- 1 views
- 04 Oct, 2022
- 2 locations
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
medication sparing effects in comparison to standard of care management in Multiple Myeloma subjects.
- 0 views
- 07 Oct, 2022
- 1 location
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
relapsed/refractory multiple myeloma subjects who received adequate standard therapy.
- 0 views
- 07 Oct, 2022
- 1 location